Inclusion Criteria:

- Patients must have histologically or cytologically confirmed non-small cell lung
cancer

- All patients must have one of the following stages: Stage IA(T1NO), and IB T2NO), II
& IIIA (N2 negative)

- No prior chemotherapy or radiation therapy for non-small cell lung cancer

- Age >18 years

- ECOG performance status <2

- Patients must have acceptable organ and marrow

- Patient must be deemed surgically and medically resectable

- Men and women of childbearing potential must be willing to use effective
contraception while on treatment and for at least 3 months thereafter.

- Ability to understand and the willingness to sign a written informed consent
document.

Exclusion Criteria:

- Patients may not be receiving any other investigational agents.

- Patients should not have received chemotherapy or radiotherapy within 3 months prior
to entry to study.

- Patients with tumors involving the superior sulcus are not eligible.

- Patients must not have post-obstructive pneumonia or other serious infection at the
time of registration or other serious underlying medical condition that would impair
the ability of the patient to receive protocol treatment.

- Prior resection of lung cancer is allowed, if at least five years have elapsed
between previous resection and registration.

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

- Pregnant women are excluded from this study. Women of childbearing potential must
have a negative pregnancy test.

- Known HIV-positive patients are excluded from the study.

- Patients with a history of known autoimmune disease are excluded from this study.